Researchers reported the development of a transferrable and integrative type I CRISPR-based platform that can efficiently edit the diverse clinical isolates of Pseudomonas aeruginosa, a superbug capable of infecting various tissues and organs and a major source of nosocomial infections. The technique can accelerate the identification of resistance determinants of multidrug resistant (MDR) pathogens and the development of novel anti-resistance strategies.
Click here for original story, Scientists harness the naturally abundant CRISPR-Cas system to edit superbugs with the hope of treating infections caused by drug resistant pathogens
Source: ScienceDaily